Substantiated obviousness arguments
Delivered prior art directly supporting invalidity positions aligned with opposition strategy.
The Challenge
A global biotechnology company developing cell-based therapies faced a critical need to assess the validity of a European patent during opposition proceedings. The matter required deep technical analysis in a highly specialized area involving human clinical trials, ischemia treatment, angiogenesis, and bone marrow-derived cell therapies.
The internal IP team required a partner capable of navigating complex biomedical literature, clinical trial databases, and global patent filings, while responding quickly to evolving questions from the European Patent Office.
The Solution
We executed a comprehensive invalidity search strategy designed to uncover high-value prior art across jurisdictions and data types.
Our approach combined deep technical analysis with iterative collaboration, ensuring alignment with the client’s evolving opposition strategy.
We delivered a preliminary report early to facilitate strategic discussion, followed by a detailed final report mapping references against key claim limitations. Throughout the engagement, we collaborated closely with the IP leadership, responding to follow-up questions and refining the search based on procedural developments.
We delivered an end-to-end infringement assessment workflow, combining advanced imaging, material analysis, and claims mapping to provide a clear, evidence-backed view of potential patent alignment.
By integrating structural and compositional analysis with patent claim interpretation, we enabled the client to move from raw device data to actionable insights. This comprehensive approach ensured that every finding directly supported their evidence-of-use evaluation.
Our Impact
Substantive prior art, detailed technical analysis, and responsive collaboration helped strengthen invalidity arguments and strategic decision-making.
In need of biotech patent search support?
We work with IP teams to identify, analyze, and assess prior art across multiple technical and non-patent sources, helping inform patent validity and opposition strategies.
The challenge
Assessing European patent validity in a complex biotech domain under evolving opposition timelines.
Why it worked
Integrated, comprehensive search strategy
Combining patent, scientific, and clinical data sources enabled comprehensive and defensible prior art discovery.
The outcome